The same higher risk for colectomies was found for biological therapy with Infliximab 51.8% vs. 22.4%, OR: 3.1 15.
4,2%, OR: 5,37, lo mismo que pacientes expuestos a terapia biológica con infliximab 51,8% vs. 22,4%, OR: 3,1 15.